These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 8801338)

  • 1. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins.
    Sharma US; Balasubramanian SV; Straubinger RM
    J Pharm Sci; 1995 Oct; 84(10):1223-30. PubMed ID: 8801338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of solubility and oral bioavailability of rutin by complexation with 2-hydroxypropyl-beta-cyclodextrin.
    Miyake K; Arima H; Hirayama F; Yamamoto M; Horikawa T; Sumiyoshi H; Noda S; Uekama K
    Pharm Dev Technol; 2000; 5(3):399-407. PubMed ID: 10934740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid-state 13C nuclear magnetic resonance spectroscopic study on amorphous solid complexes of tolbutamide with 2-hydroxypropyl-alpha- and -beta-cyclodextrins.
    Kimura K; Hirayama F; Arima H; Uekama K
    Pharm Res; 1999 Nov; 16(11):1729-34. PubMed ID: 10571279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats.
    Arima H; Yunomae K; Miyake K; Irie T; Hirayama F; Uekama K
    J Pharm Sci; 2001 Jun; 90(6):690-701. PubMed ID: 11357172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation, characterization, molecular modeling and in vitro activity of paclitaxel-cyclodextrin complexes.
    Alcaro S; Ventura CA; Paolino D; Battaglia D; Ortuso F; Cattel L; Puglisi G; Fresta M
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1637-41. PubMed ID: 12039580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solubility and mass and nuclear magnetic resonance spectroscopic studies on interaction of cyclosporin A with dimethyl-alpha- and -beta-cyclodextrins in aqueous solution.
    Miyake K; Hirayama F; Uekama K
    J Pharm Sci; 1999 Jan; 88(1):39-45. PubMed ID: 9874700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some pharmaceutical properties of 3-hydroxypropyl- and 2,3-dihydroxypropyl-beta-cyclodextrins and their solubilizing and stabilizing abilities.
    Yoshida A; Yamamoto M; Irie T; Hirayama F; Uekama K
    Chem Pharm Bull (Tokyo); 1989 Apr; 37(4):1059-63. PubMed ID: 2766408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stabilizing and solubilizing effects of sulfobutyl ether beta-cyclodextrin on prostaglandin E1 analogue.
    Uekama K; Hieda Y; Hirayama F; Arima H; Sudoh M; Yagi A; Terashima H
    Pharm Res; 2001 Nov; 18(11):1578-85. PubMed ID: 11758766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-beta-cyclodextrin.
    Kim JH; Lee SK; Ki MH; Choi WK; Ahn SK; Shin HJ; Hong CI
    Int J Pharm; 2004 Mar; 272(1-2):79-89. PubMed ID: 15019071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of some pharmaceutical properties of DY-9760e by sulfobutyl ether beta-cyclodextrin.
    Nagase Y; Hirata M; Wada K; Arima H; Hirayama F; Irie T; Kikuchi M; Uekama K
    Int J Pharm; 2001 Oct; 229(1-2):163-72. PubMed ID: 11604269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of water-solubility and bioactivity of paclitaxel using modified cyclodextrins.
    Hamada H; Ishihara K; Masuoka N; Mikuni K; Nakajima N
    J Biosci Bioeng; 2006 Oct; 102(4):369-71. PubMed ID: 17116587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel.
    Constantinides PP; Lambert KJ; Tustian AK; Schneider B; Lalji S; Ma W; Wentzel B; Kessler D; Worah D; Quay SC
    Pharm Res; 2000 Feb; 17(2):175-82. PubMed ID: 10751032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inclusion complex of 3,9-bis(N,N-dimethylcarbamoyloxy)-5H-benzofuro[3,2-c]quinoline-6-one (KCA-098) with heptakis(2,6-di-O-methyl)-beta-cyclodextrin: interaction and dissolution properties.
    Yamada T; Imai T; Ouchi K; Otagiri M; Hirayama F; Uekama K
    Chem Pharm Bull (Tokyo); 2000 Sep; 48(9):1264-9. PubMed ID: 10993223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study on inclusion complexation of maltosyl-beta-cyclodextrin, heptakis(2,6-di-O-methyl)-beta-cyclodextrin and beta-cyclodextrin with fucosterol in aqueous and solid state.
    Acartürk F; Imai T; Saito H; Ishikawa M; Otagiri M
    J Pharm Pharmacol; 1993 Dec; 45(12):1028-32. PubMed ID: 7908969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the interaction of clobazam with cyclodextrins in solution and in the solid state.
    Nakai Y; el-Said Aboutaleb A; Yamamoto K; Saleh SI; Ahmed MO
    Chem Pharm Bull (Tokyo); 1990 Mar; 38(3):728-32. PubMed ID: 2347015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of water-soluble beta-cyclodextrin derivatives as carriers of anti-inflammatory drug biphenylylacetic acid in rectal delivery].
    Arima H; Kondo T; Irie T; Hirayama F; Uekama K; Miyaji T; Inoue Y
    Yakugaku Zasshi; 1992 Jan; 112(1):65-72. PubMed ID: 1578346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced rectal absorption and reduced local irritation of the anti-inflammatory drug ethyl 4-biphenylylacetate in rats by complexation with water-soluble beta-cyclodextrin derivatives and formulation as oleaginous suppository.
    Arima H; Kondo T; Irie T; Uekama K
    J Pharm Sci; 1992 Nov; 81(11):1119-25. PubMed ID: 1447717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cyclodextrins on the solubility and stability of candesartan cilexetil in solution and solid state.
    Al Omari AA; Al Omari MM; Badwan AA; Al-Sou'od KA
    J Pharm Biomed Anal; 2011 Feb; 54(3):503-9. PubMed ID: 20971593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of solubility and oral bioavailability of 2-(N-cyanoimino)-5-[(E)-4-styrylbenzylidene]-4-oxothiazolidine (FPFS-410) with antidiabetic and lipid-lowering activities in dogs by 2-hydroxypropyl-beta-cyclodextrin.
    Hara T; Hirayama F; Arima H; Yamaguchi Y; Uekama K
    Chem Pharm Bull (Tokyo); 2006 Mar; 54(3):344-9. PubMed ID: 16508189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in the development of alternative pharmaceutical formulations of taxanes.
    Nuijen B; Bouma M; Schellens JH; Beijnen JH
    Invest New Drugs; 2001 May; 19(2):143-53. PubMed ID: 11392448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.